The variability in clinical manifestation and treatment response in asthmatic patients is considered to result from its heterogeneous mechanisms. [1] [2] [3] There are many clinical phenotypes of asthma: atopic (includes both eosinophilic and noneosinophilic), nonatopic, eosinophilic nonatopic, and neutrophilic. 4 It is now generally accepted that atopic and eosinophilic nonatopic asthma are mediated by a type 2 immune response (an immune response that results in production of IL-4, IL-5, and IL-13 among others). 5 Although T H 2 cells are considered to play a central role in atopic asthma, it is likely that other type 2 cytokine-producing cells, such as type 2 innate lymphoid cells and CD8 T cells, and natural killer T cells also contribute to this phenotype. [6] [7] [8] Genome-wide transcriptomic analysis of airway epithelial cells led to identification of T H 2-high and T H 2-low endotypes of asthma. 5 The T H 2-high endotype manifested with increased expression of IL-13 signature genes (periostin, CLCA1, and serpin 2B) in airway epithelial cells. Their T cells produced increased amounts of IL-5. Patients with T H 2-low asthma did not show increased expression of type 2 cytokines. Another study reported increased expression of IFN-g 1 CD4 (T H 1) cells in a subgroup of patients with severe asthma. 8 Differentiated T H cells manifest plasticity in their phenotype. 9 T H 2 cells can transdifferentiate into T H 2/T H 17 cells.
The presence of dual-positive T H 2/T H 17 cells has been described in the blood of asthmatic patients. 10 Using flow cytometric detection of bronchoalveolar lavage (BAL) cytokineexpressing T cells, we recently reported 3 endotypes of asthma: T H 2-predomnant, T H 2/T H 17-predominant, and T H 2/T H 17-low asthma.
11 T H 2/T H 17-predominant asthma was characterized by the dominant presence of dual-positive T H 2/T H 17 cells in BAL fluid. These dual-positive T H 2/T H 17 cells simultaneously produced IL-4 and IL-17. The cytokine milieu that favors the development of T H 2/T H 17 cells in the airways is unknown. In animal studies T H 17 cells are associated with neutrophilic asthma. 12, 13 We anticipated a mixed eosinophilic and neutrophilic phenotype in patients with T H 2/T H 17-predominant asthma. Instead, we observed increased eosinophil but not neutrophil counts in BAL fluid from patients with T H 2/T H 17-predominant asthma. This study suggested a different mechanism for neutrophilic asthma in human subjects. The objective of this study was to define the cytokine/mediator milieu that contributes to T H 2/T H 17-predominant, T H 2/T H 17-low, and neutrophilic asthma.
METHODS

Human subjects
The study subjects were recruited from the outpatient clinics of National Jewish Health. The study protocol for bronchoscopy and BAL was approved by the institutional review board. Informed consent was obtained from the study subjects. Patients were allowed to continue their routine medication. The biological samples for this study (BAL fluid and cells) were from the same cohort of 60 patients described in the previously published article.
11 This 
Processing of BAL cells and flow cytometry
Bronchoscopy and BAL were performed, as described previously. 11, 14 BAL fluid was processed immediately. Cells were isolated by means of centrifugation. Supernatant fluid was aliquoted into small samples and frozen. Cells were fixed immediately in 4% paraformaldehyde and processed for flow cytometry, as described previously. 11 In a small group of patients, cells were cultured with anakinra (a recombinant IL-1 receptor [IL-1R] antagonist protein from ProSpec, East Brunswick, NJ) or medium for 3 days and then analyzed by means of flow cytometry.
Airway epithelial cell culture and function
The human immortalized airway epithelial cell line BEAS-2B and freshly isolated human bronchial epithelial cells from asthmatic patients (obtained by means of bronchial brushing) were grown in the BEBM medium (Lonza, Wetzlar, Germany) with the addition of the growth factor-enriched supplement BEGM (Cambrex, East Rutherford, NJ), and the medium was changed every 3 days, as described previously. 15 Before stimulation, cells were trypsinized and then plated at 4 3 10 4 cells/mL in a 6-well tissue culture plate. BEAS-2B cells were stimulated with a subthreshold dose of LPS (0.25 mg/ mL) with and without additional cytokines/growth factors (IL-1a, IL-4, IL-6, GM-CSF, IL-17A, and C3a at 10 ng/mL each) for the indicated period of time. Freshly isolated human bronchial epithelial cells were cultured with IL-1a, IL-6, GM-CSF, and C3a (at 10 ng/mL each) and their combinations but without LPS for 48 hours. In additional experiments cells were cultured with and without the p38 MAPK inhibitor SB212190 (10 mmol/L). Supernatants were collected and assayed for secreted cytokines by means of ELISA.
ELISA
We performed ELISA for the following cytokines and mediators: IL-1a, IL-1b, IL-6, IL-8, IL-17A, IL-21, IL-23, granulocyte colony-stimulating factor (G-CSF), GM-CSF, TNF-a, C3a, myeloperoxidase, serum amyloid A, and uric acid. The foregoing cytokines/mediators were assayed in undiluted BAL fluid by using ELISA kits or paired (capture and detection) antibodies, according to the supplier's instruction. GM-CSF (sensitivity, 7.8 pg/mL), TNF-a (sensitivity, 7.8 pg/mL), IL-1a (sensitivity, 7.8 pg/mL), IL-6 (sensitivity, 7.8 pg/mL), IL-8 (sensitivity, 15.6 pg/mL), IL-17A (sensitivity, 3.9 pg/mL), and IL-21 (sensitivity, 31.3 pg/mL) were from BioLegend (San Diego, Calif); IL-1b (sensitivity, 3.9 pg/mL), G-CSF (sensitivity, 31.3 pg/mL), and myeloperoxidase (sensitivity, 62.5 pg/mL) were from R&D Systems (Minneapolis, Minn); C3a (sensitivity, 0.32 ng/mL) was from eBioscience (San Diego, Calif); the Uric Acid Assay kit (sensitivity, 0.5 mmol/L) was from Cayman Chemical Company (Ann Arbor, Mich); the serum amyloid A kit (sensitivity: 0.4, ng/mL) was from Abcam (Cambridge, Mass); and the IL-23 kit (sensitivity, 3 pg/mL) from MyBiosource (San Diego, Calif).
Statistical analyses
Comparisons between the study groups were done by using the MannWhitney U test. Comparisons among multiple study groups were performed by using the Kruskal-Wallis test. The Pearson correlation coefficient was used to calculate the correlation coefficient. Table E1 in this article's Online Repository at www.jacionline.org). We wanted to define the cytokine milieu that favored the development of dual-positive T H 2/T H 17 cells in the airways. A previous study showed that IL-1, IL-6, IL-21, and IL-23 were capable of inducing T H 2/T H 17 cell differentiation. 10 For this reason, we assayed BAL fluid from this cohort of 60 asthmatic patients for these cytokines. IL-21 was undetectable. IL-1a (Fig 1, A) and IL-23 (Fig 1, D) levels were selectively increased in patients with T H 2/T H 17-low and T H 2/T H 17-predominant asthma, respectively. IL-1b (Fig 1,  B) and IL-6 (Fig 1, C ) levels were increased in both patients with T H 2/T H 17-predominant asthma and those with T H 2/T H 17-low asthma compared with patients with T H 2-predominant asthma. IL-6 levels were higher in patients with T H 2/T H 17-predominant asthma compared with those with T H 2/T H 17-low asthma.
RESULTS
Danger-associated molecular patterns in the airways of patients with the different asthma subtypes Next, we examined the mechanism of increased production of IL-1b and IL-6 in patients with T H 2/T H 17-predominant asthma. Many environmental toxicants induce airway stress and trigger the production of danger-associated molecular patterns (DAMPs). 16, 17 DAMPs influence the production of immunomodulatory cytokines. [18] [19] [20] [21] [22] We examined 3 DAMPs in BAL fluid from the 3 asthmatic groups. Selection of these DAMPs was based on their documented involvement in T H 2-and T H 17-type inflammation. [19] [20] [21] [22] C3a and serum amyloid A, but not uric acid, levels were increased in both patients with T H 2/T H 17-predominant asthma and those with T H 2/T H 17-low asthma (Fig 2) . Their levels were higher in patients with T H 2/T H 17-predominant asthma compared with those with T H 2/T H 17-low asthma.
Clinical correlation of cytokines and DAMPs with T H 2/T H 17
Of the foregoing cytokines and DAMPs, only IL-1b and C3a levels significantly correlated with T H 2/T H 17 cell counts (Fig 3, A and B). C3a levels also correlated (r 5 0.69, P < .001) with IL-1b levels (Fig 3, C) . Because IL-1b levels strongly correlated with T H 2/T H 17 cell counts, we sought to determine the expression level of IL-1R on T H 2/T H 17 cells ex vivo and compared this with expression levels on other cells. Both T H 2/T H 17 cells and T H 17 cells demonstrated the highest level of IL-1R expression in BAL fluid compared with T H 2 cells (Fig 3, C) . IL-1b activates multiple signaling pathways, one of which is the p38 MAPK pathway. 23 We observed a high level expression of the phosphorylated form (activating phosphorylation) of p38 MAPK in T H 2/ T H 17 and T H 17 cells (Fig 3, D) . We recognize that p38 MAPK is not specific for IL-1b and is activated by many molecules. To define the role of IL-1b further, we cultured BAL cells from patients with moderate-to-severe (as per National Asthma Education and Prevention Program Expert Panel Report 3 guidelines) asthma with anakinra (recombinant IL-1R antagonist protein, brand name Kineret) and measured IL-4/IL-17 1 cell counts. Anakinra inhibited the expression of dual IL-4/IL-17 1 CD4 T cells in BAL fluid in a dose-dependent manner (Fig 3, E) . To determine whether IL-1b was responsible for p38 MAPK signaling, we cultured BAL fluid cells from patients with moderate-to-severe (as per National Asthma Education and Prevention Program Expert Panel Report 3 guidelines) asthma with anakinra for 24 hours and analyzed the expression of phospho-p38 in CD4 T cells by using flow cytometry. Anakinra significantly inhibited phospho-p38 in a dose-dependent manner (Fig 3, F) . In aggregate, these results suggest that IL-1b plays an important role in the differentiation, maintenance, or both of T H 2/T H 17 cells in a subgroup of asthmatic patients.
T H 2/T H 17-low but not T H 2/T H 17-predominant asthma is associated with increased BAL fluid neutrophil counts
In mouse studies a T H 17 immune response was associated with neutrophilic asthma.
12, 13 We anticipated increased airway neutrophil counts in patients with T H 2/T H 17-predominant asthma. An analysis of BAL fluid neutrophil counts revealed that T H 2/T H 17-low asthma but not T H 2/T H 17-predominant asthma was associated with neutrophilic asthma. Patients with T H 2/T H 17-low asthma had significantly higher numbers of BAL neutrophils: 16.1% 6 4.4% compared with 4% 6 1.8% in T H 2/ T H 17-predominant and 2.5% 6 0.5% in T H 2-predominant endotypes (Fig 4, A) . An analysis of individual data points indicates clustering and separation of neutrophil-high patients from neutrophil-low patients (Fig 4, A) . Based on the clustering pattern of BAL fluid neutrophils in these 3 groups, we set a threshold number of 7 for patients with neutrophilic asthma. When this threshold number is applied, only 1 patient from the group with T H 2/T H 17-predominant asthma and none from the group with T H 2-predominant asthma but 10 patients from the group with T H 2/T H 17-low asthma had neutrophilic asthma. To further confirm neutrophilic inflammation, we examined BAL fluid myeloperoxidase levels in the same patients. The myeloperoxidase from asthmatic patients were analyzed by using flow cytometry for expression of CD4 and intracellular IL-4, IL-17, IL-1R, and phospho-p38 MAPK. *P < .04 (n 5 6). E, Inhibition of T H 2/T H 17 cells by using anakinra. BAL fluid cells were cultured with increasing concentrations of anakinra for 3 days and then analyzed for dual IL-4/IL-17 1 CD4 T cells by using flow cytometry. Each symbol represents an asthmatic patient. P values (on the top of the graph) were calculated by using the Kruskal-Wallis test. F, Inhibition of phospho-p38 MAPK in BAL T cells by anakinra. BAL cells were cultured with anakinra for 24 hours and then examined for expression of phospho-p38 MAPK in CD4 T cells by using flow cytometry. Each symbol represents an asthmatic patient. P values were calculated by using the Kruskal-Wallis test.
level was similarly increased in patients with T H 2/T H 17-low asthma compared with the other 2 groups (Fig 4, B) . The myeloperoxidase level highly correlated (r 5 0.89, P < .001) with BAL fluid neutrophil counts. IL-8 (CXCL8) is a chemokine that critically drives neutrophilic inflammation. [24] [25] [26] We measured IL-8 levels in BAL fluid from the study groups. IL-8 levels were highest in the T H 2/T H 17-low group and lowest in the T H 2-predominant group (Fig 4, C) . The distribution of individual data points also suggested clustering and separation of IL-8-high patients from IL-8-low patients. When we used an arbitrary cutoff point of 200 pg/mL, only 1 patient from the group with T H 2/T H 17-predominant asthma, no patients from the group with T H 2-predominant asthma, and 10 patients from the group with T H 2/T H 17-low asthma had high IL-8 levels, which was similar to that observed for neutrophils. As expected, BAL fluid IL-8 levels strongly correlated (r 5 0.88, P 5 .00001) with BAL fluid neutrophil counts (Fig 4, D) , suggesting that IL-8 contributed to neutrophilic inflammation. The absence of neutrophilic inflammation in the T H 2/T H 17-predominant group was surprising. Because IL-17 is produced by dual-positive T H 2/T H 17 cells, which also produce high levels of IL-4, we asked whether IL-4 and IL-13 affected LPS-induced epithelial production of IL-8, the major inducer of neutrophilic inflammation. Both IL-4 and IL-13 significantly stimulated IL-8 production at low doses but inhibited this production at high doses in BEAS-2B epithelial cells (Fig 4, E) . Our results agree with those of a recent report, 27 which suggested an inhibitory role of IL-4/IL-13. We asked whether this relationship existed in vivo. To this goal, we measured IL-4 and IL-8 levels in 42 BAL samples obtained from all 3 study groups. We found a negative correlation between IL-4 and IL-8 levels (Fig 4, F) . Note that the concentration of IL-4 in BAL fluid was relatively low, which is likely due to the dilution effect of the large volume (120 mL) of saline that was used for BAL. The results provide a mechanistic explanation for the lack of neutrophilic inflammation in patients with IL-4-high T H 2/ T H 17-predominant asthma.
Role of cytokines and DAMPs in patients with neutrophilic asthma
In addition to IL-8, many other cytokines either directly or indirectly regulate neutrophilic inflammation. They include IL-1a, IL-1b, IL-6, IL-17A, G-CSF, GM-CSF, and TNF-a. [28] [29] [30] [31] [32] IL-1a, IL-1b, and IL-6 levels were increased in patients with T H 2/T H 17-low asthma (Fig 1, A-C) . Next, we measured IL-17A, G-CSF, GM-CSF, and TNF-a levels in BAL fluid from the 3 study groups. TNF-a was undetectable in BAL fluid from the asthmatic patients. Levels of G-CSF and GM-CSF, but not IL-17A, were increased in patients with T H 2/T H 17-low asthma compared with those in patients with T H 2-and T H 2/T H 17-predominant asthma (Fig 5, A-C) . IL-1a, GM-CSF, IL-6, G-CSF, and C3a (in order of the strength of correlation) levels correlated (Fig 4, B) and IL-8 (Fig 4, C ) levels in patients with T H 2-predominant, T H 2/T H 17-predominant, and T H 2/T H 17-low asthma. D, Correlation of BAL fluid neutrophil counts and IL-8 levels in patients with T H 2/T H 17-low asthma. E, Effect of type 2 cytokines on IL-8 production. Airway epithelial BEAS-2B cells were cultured with increasing concentrations of IL-4 and IL-13 for 3 days, and the culture supernatant was assayed for IL-8 by using ELISA. **P < .05 (n 5 4). F, Correlation between IL-4 and IL-8 levels in BAL fluid from all 3 study groups (n 5 42).
with IL-8 levels (Table I) . G-CSF, IL-1a, IL6, GM-CSF and C3a levels correlated with BAL fluid neutrophil counts. IL-1b, serum amyloid A, and uric acid levels did not correlate with neutrophil counts and IL-8 levels.
Effect of cytokines and DAMPs on IL-8 production by airway epithelial cells
Next, we studied the effect of BAL neutrophil-associated cytokines/mediators (ie, IL-1a, IL-6, GM-CSF, and C3a; Table I) on epithelial IL-8 production. We used 2 different cell types: the immortalized human bronchial epithelial cell line BEAS-2B and freshly isolated human bronchial epithelial cells from asthmatic patients obtained by means of bronchial brushing. Freshly isolated human bronchial epithelial cells spontaneously produced significant quantities of IL-8 when cultured in medium alone (Fig 5, D) . In contrast, BEAS-2B cells required priming with a subthreshold dose of LPS to induce IL-8 production. For this reason, all BEAS-2B cultures were performed with the subthreshold dose of LPS. In both cell types IL-1a was the strongest (Fig 5, A) , GM-CSF (Fig 5, B) , and G-CSF (Fig 5, C) in BAL fluid from patients with T H 2-predominant, T H 2/T H 17-predominant, and T H 2/T H 17-low asthma. D, Effect of cytokines/mediators on epithelial IL-8 production. Freshly isolated human bronchial epithelial cells (HBE) and BEAS-2B cells were cultured with various cytokines/mediators (10 ng/mL) singly or in combination for 3 days. The BEAS-2B cell cultures were primed with a subthreshold dose of LPS (0.25 mg/mL). Culture supernatants were assayed for IL-8 by means of ELISA. *P < .05 (n 5 4). E, Freshly isolated human bronchial epithelial cells were cultured with dimethyl sulfoxide (DMSO) or SB212190 (10 mmol/L) in the presence of IL1a (10 ng/mL) for 3 days. Culture supernatant was assayed for IL-8 by using ELISA. *P < .05 (n 5 3).
inducer of IL-8. IL-6 and C3a induced modest levels of IL-8 production by LPS-primed BEAS-2B cells, whereas only C3a induced low levels of IL-8 in freshly isolated airway epithelial cells. GM-CSF did not induce IL-8 in either cell types. A combination of IL-1a with the other biomolecules increased IL-8 production, but the increase was less than additive, suggesting that epithelial IL-8 production perhaps reached a peak. The results provide a mechanistic understanding of induction of neutrophilic inflammation by IL-6, C3a, and especially by IL1a. As mentioned previously, IL-1 (both a and b) activates phospho-p38 MAPK as one of the downstream signaling pathways.
To determine whether this pathway was involved in IL-8 production, we incubated freshly isolated human airway epithelial cells with the p38 MAPK inhibitor SB212190 and then stimulated with IL-1a. SB212190 significantly inhibited IL-8 production (Fig 5, E) , although the inhibition was modest, suggesting a role for other signaling pathways. Nonetheless, the result demonstrated a role for the p38 MAPK pathway in IL-1a activation of epithelial cells.
Role of infection in patients with neutrophilic asthma
BAL fluid from all study groups including T H 2-predominant, T H 2/T H 17-predominant, and T H 2/T H 17-low groups were cultured for microbial growth (bacteria, fungi, and mycobacteria). In addition, a sample of the BAL cells and bronchial brushing was analyzed for atypical infection (Mycoplasma pneumoniae and Chlamydophila pneumoniae) and respiratory tract viruses by using quantitative PCR. The foregoing tests were performed as a part of the clinical workup for refractory asthma at National Jewish Health. We analyzed these data for our study population. None of the patients from the T H 2-predominant and T H 2/T H 17-predominant groups had positive results for microbial organisms. The patients from the T H 2/T H 17-low group, whose BAL neutrophil counts were greater than 7%, showed a higher frequency of microbial presence in BAL fluid (Table II) . Five of 10 patients from this neutrophilic subgroup of patients with T H 2/T H 17-low asthma had bacterial growth, and 1 had a viral infection. None of them had positive results for fungal, mycobacterial, or atypical microorganisms. It should be noted that none of the patients with positive results for bacterial growth had current or recent symptoms of an acute infection (fever, leukocytosis, sore throat, coryza, or myalgia).
Clinical characteristics of patients with neutrophilic and nonneutrophilic T H 2/T H 17-low asthma
In the previous publication we compared the clinical data of the 3 study groups. 11 In this article we compared the clinical data of patients with neutrophilic and nonneutrophilic asthma belonging to the T H 2/T H 17-low group. We compared age, sex, body mass index, blood neutrophil counts, BAL fluid and blood eosinophil counts, total IgE levels, allergy skin test results for environmental allergens, FEV 1 (as a percentage), FEV 1 /forced vital capacity ratio, methacholine PC 20 , and Asthma Control Test scores (Table III) . There was no significant difference in all these parameters between patients with neutrophilic and those with nonneutrophilic T H 2/T H 17-low asthma. Both study groups were characterized by low levels of total IgE and relatively (compared with T H 2-predominant and T H 2/T H 17-predominant asthma) 11 lower levels of skin test positivity and blood eosinophil counts. Both groups had baseline airway obstruction and low abnormal Asthma Control Test scores.
DISCUSSION
In this study we investigated putative mechanisms of T H 2/ T H 17-predominant and T H 2/T H 17-low asthma using BAL samples from a previously immunophenotyped cohort of asthmatic patients. T H 2/T H 17-predominant asthma represented 26% of the entire cohort of patients with refractory asthma (see Fig E2 in this article's Online Repository at www.jacionline.org). Patients with T H 2/T H 17-predominant asthma had increased eosinophil counts and IgE levels and advanced median age. 11 This group is largely similar to what has previously been described as lateonset eosinophilic asthma (see Fig E3 in this article' s Online Repository at www.jacionline.org). Here we show that T H 2/ T H 17-predminant asthma was associated with increased levels of IL-1b, IL-6, IL-23, C3a, and serum amyloid A in BAL fluid. All these biomolecules are known to induce T H 17.
9 IL-1b is considered one of the most critical T H 17-inducing cytokines in human subjects. 33 IL-1b, IL-6, and IL-23 have been shown to induce human T H 2/T H 17 cells in vitro, 10 which has direct relevance for this article. Of these 3 cytokines, only IL-1b levels correlated with T H 2/T H 17 cell counts in the airways. T H 2/ T H 17 cells expressed higher levels of IL-1R and phospho-p38 MAPK, indirectly supporting a role for IL-1b. Finally, blockade of the IL-1R by anakinra (Kineret) inhibited the expression of dual IL-4/IL-17 1 cells in BAL fluid from asthmatic patients. The latter data suggest that IL-1b is likely to play a causative role in T H 2/T H 17 development, maintenance, or both. The results also suggest that IL-1b inhibition with anakinra or similar drugs, such as rilonacept and canakinumab, could benefit patients with this subtype of asthma.
Previous studies showed that C3a induced IL-1b 34 and conversely that IL-1b induced C3a, 35 suggesting the existence of a positive feedback circuit under certain circumstances. Variants of the C3 gene were associated with asthma in African Caribbean subjects. 36 Its expression level was reported to be increased in asthmatic patients, 37 but it was unclear whether C3a favored one particular subtype of asthma. We found that C3a levels were highest in patients with T H 2/T H 17-predominant asthma. There was a strong correlation between C3a and IL-1b levels, and a significant correlation between C3a levels and T H 2/T H 17 cell counts. The results suggest that C3a can contribute to T H 2/ T H 17-predominant asthma through the induction of IL-1b. IL-6 levels were increased in patients with T H 2/T H 17-predominant asthma. However, this did not correlate with T H 2/T H 17 cells. IL-6 signals through signal transducer and activator of transcription (STAT) 3. We reported increased levels of pSTAT3, which colocalized with pSTAT6 in patients with T H 2/T H 17-predominant asthma. We recognize that pSTAT3 signaling is not specific for IL-6. Nonetheless, its increased levels raise the possibility that IL-6 was involved in T H 2/T H 17 development. We identified a distinct subgroup of T H 2/T H 17-low asthma, which was characterized by increased BAL fluid neutrophil counts (see Fig E2) and increased frequency of infection. This group likely represents the previously identified neutrophilic asthma (see Fig E3) . 4 Animal studies suggested that neutrophilic asthma was associated with a T H 17 immune response. 12, 13 Although we and many other groups reported increased IL-17A levels in BAL fluid from asthmatic patients, 11, 38, 39 we were unable to detect increased T H 17 cell counts in BAL fluid. 11 Instead, IL-17A was produced by dual-positive T H 2/T H 17 cells, as well as other cells (eg, gd T cells), in asthmatic patients. We anticipated that T H 2/T H 17-predominant asthma would be associated with neutrophilic asthma. Instead, it was T H 2/T H 17-low asthma that was associated with neutrophilic asthma. We provided a mechanistic understanding for this unexpected finding. We showed that IL-4 and IL-13 inhibited the production of IL-8, a critical mediator of neutrophilic asthma. Our result is in agreement with the recent reports on the inhibition of proneutrophilic chemokines 27 and growth factors 40 by type 2 cytokines. We found a strong positive correlation of BAL fluid IL-8 levels with BAL fluid neutrophil counts in patients with T H 2/T H 17-low neutrophilic asthma. Previous studies demonstrated an association of sputum IL-8 levels with neutrophilic asthma. [41] [42] [43] IL-8 frequently functions downstream of other cytokines, such as IL-1, IL-6, and GM-CSF. IL-1a, IL-6, and, to a lesser extent, GM-CSF levels positively correlated with BAL fluid IL-8 levels and neutrophil counts. Of these cytokines, only IL-1a strongly induced IL-8 production by epithelial cells. The results of this study and a number of previous studies 28, 29, 42, 44 suggest that IL-1a, a mucosal alarmin, plays a central role in orchestrating neutrophilic inflammation in asthmatic patients. This is similar to IL-33, another alarmin, triggering a type 2 innate lymphoid cell and/or T H 2-type inflammation. 45 Both IL-1a and IL-33 are produced under basal conditions by human epithelial cells, localized to the nucleus, and released as a result of epithelial stress. Like IL-33, IL-1a is also produced by hematopoietic cells under inflammatory conditions, which further amplifies inflammation. An unexpected finding is the lack of correlation of IL-1b levels with neutrophilic asthma. Our data suggest a differential regulation of neutrophilic asthma and T H 2/T H 17-predominant asthma by IL-1a and IL-1b, respectively.
In an effort to investigate the mechanism of neutrophilic asthma, we examined microbial organisms in airway fluid and cells. Our studies detected a frequent association of bacterial infection with neutrophilic asthma. We believe that these patients had localized subclinical infections. This is further supported by the fact that despite having increased neutrophil counts in BAL fluid, these patients did not have blood neutrophilia. These findings have implications not only for pathogenesis but also for asthma management. It should be noted that the frequency of T H 2/T H 17-low neutrophilic asthma is relatively low and represents 16.6% of the entire cohort. The subclinical infection was present in 55% of these patients, which represents 10% of the entire cohort.
Although prolonged antibiotic therapy has been tried in refractory asthma with variable results, 46 -48 these studies did not target patients with neutrophil-high or IL-8-high asthma. 1  10  200  -----2  56  141  -Rhinovirus  ---3  11  295  -----4  7 Our coinvestigators published a study on refractory asthma, in which they identified 5 clinical phenotypes. 14 One phenotype was termed subacute bacterial infection, which represented 25 of the 58 subjects. A pathogen identification was needed for inclusion into this phenotype. The group markedly improved both lung function and asthma control with prolonged directed antimicrobial therapy. It is likely that prolonged antibiotic therapy will be specifically beneficial to patients with neutrophil-high T H 2/ T H 17-low asthma.
This study also raises questions about subclinical infection in patients with increased airway neutrophil counts and IL-8 levels, who do not have a positive culture result in conventional microbiological approaches because of their low sensitivity. It would be interesting to determine whether PCR or nextgeneration sequencing approaches would detect subclinical infection in many of these culture-negative patients. It is likely that mild neutrophilic inflammation of the airways is independent of infection and reflects chronic local and/or systemic inflammation. Significant correlation of multiple cytokines with BAL neutrophilia supports this notion. The subgroup of patients with BAL fluid neutrophilia but without infection is likely to benefit from therapies targeting IL-8, IL-6, and IL-1a and their receptors.
We recognize limitations of this study. The low sample size creates a major problem when probing a highly heterogeneous disease, such as asthma. The patient population at National Jewish Health is highly skewed toward refractory asthma. Thus the frequency of neutrophilic asthma in our study population might not reflect that of a general population. We studied patients at a single time point of their chronic illness. Thus the observed abnormalities might not be linked to the pathogenesis but to the concurrent environmental factors, infection, or both. The patient population was of advanced age, which could secondarily affect the outcome because of chronic inflammation. We recognize that phenotypes change over age, which might reflect the changing nature of the underlying mechanism. There are significant differences in FEV 1 , PC 20 for methacholine, blood eosinophil counts, and medication taken among study groups, as reported previously, 11 which could have affected the study outcomes. Although we used the best available assays and reagents, their sensitivity and specificity are far from being ideal. We recognize these limitations. Nonetheless, we believe that the results of this study shed new light on the mechanism of 2 immune endotypes of asthma: T H 2/T H 17-predominant asthma and neutrophilic T H 2/T H 17-low asthma.
Clinical implications: This study uncovers a critical role for the IL-1b pathway in development of T H 2/T H 17-predominant asthma. This subtype of asthma is likely to benefit from an IL-1 inhibitor-like drug (eg, anakinra). Neutrophilic asthma represents a subtype of T H 2/T H 17-low asthma. A subgroup of neutrophilic asthma is associated with subclinical infection and an infection-inducible cytokine profile. Antimicrobial agents and biologics targeting specific cytokines are likely to benefit patients with this subgroup of asthma. 
